These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8845568)

  • 1. Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis.
    Boccadoro M; Pileri A
    Baillieres Clin Haematol; 1995 Dec; 8(4):705-19. PubMed ID: 8845568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
    International Myeloma Working Group
    Br J Haematol; 2003 Jun; 121(5):749-57. PubMed ID: 12780789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma.
    Kyle RA
    Hematol Oncol Clin North Am; 1997 Feb; 11(1):71-87. PubMed ID: 9081205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic studies useful for the diagnosis and monitoring of plasma cell dyscrasias.
    Veillon DM; Cotelingam JD
    Contrib Nephrol; 2007; 153():25-43. PubMed ID: 17075222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benign and malignant monoclonal gammopathies.
    Carney DN; Bunn PA
    Prim Care; 1980 Sep; 7(3):369-94. PubMed ID: 6777792
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
    Mayo MM; Johns GS
    Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review.
    Pertuiset E; Bellaiche L; Lioté F; Laredo JD
    Rev Rhum Engl Ed; 1996 Dec; 63(11):837-45. PubMed ID: 9010972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma cell dyscrasias: diverse presentations, pathophysiology, and management.
    Eichner ER
    Postgrad Med; 1980 Jun; 67(6):44-9, 53-4, 57-8 passim. PubMed ID: 6769101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow imaging in plasma cell dyscrasias: review of 130 cases.
    Feggi LM; Scutellari PN; Prandini N; Orzincolo C; Spanedda R
    J Nucl Biol Med (1991); 1992; 36(4):303-8. PubMed ID: 1296769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.
    Greipp PR; Witzig TE; Gonchoroff NJ; Habermann TM; Katzmann JA; O'Fallon WM; Kyle RA
    Mayo Clin Proc; 1987 Nov; 62(11):969-77. PubMed ID: 3118117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma.
    Ong F; Hermans J; Noordijk EM; Kluin-Nelemans JC
    Ann Hematol; 1995 Jan; 70(1):19-24. PubMed ID: 7827202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management.
    Zulian GB
    Semin Hematol; 1997 Jan; 34(1 Suppl 1):29-39. PubMed ID: 9122744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
    Milani P; Palladini G; Merlini G
    Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.
    Gavriatopoulou M; Musto P; Caers J; Merlini G; Kastritis E; van de Donk N; Gay F; Hegenbart U; Hajek R; Zweegman S; Bruno B; Straka C; Dimopoulos MA; Einsele H; Boccadoro M; Sonneveld P; Engelhardt M; Terpos E
    Leukemia; 2018 Sep; 32(9):1883-1898. PubMed ID: 30038381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma cell dyscrasias and the head and neck.
    Batsakis JG; Medeiros JL; Luna MA; El-Naggar AK
    Ann Diagn Pathol; 2002 Apr; 6(2):129-40. PubMed ID: 12004363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
    Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
    Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Laboratory diagnosis of myeloma disease (review of the literature)].
    Lugovskaia SA
    Vrach Delo; 1982 Jan; (1):57-61. PubMed ID: 7041423
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary splenic presentation of plasma cell dyscrasia: report of two cases.
    Horny HP; Saal J; Kaiserling E
    Hematol Pathol; 1992; 6(3):155-60. PubMed ID: 1429343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3. The laboratory investigation of monoclonal gammopathies.
    Kyle RA; Greipp PR
    Mayo Clin Proc; 1978 Nov; 53(11):719-39. PubMed ID: 101720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cell dyscrasias: current status.
    Kyle RA; Greipp PA
    Crit Rev Oncol Hematol; 1988; 8(2):93-152. PubMed ID: 3046767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.